Compounds > ondansetron

ondansetron and casopitant

ondansetron has been researched along with casopitant in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (36.36)	29.6817
2010's	7 (63.64)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adams, L; Blum, R; Johnson, B; Lates, C; Lebowitz, P; Lu, E; Zhang, K	1
Bandekar, RR; Dediu, M; Grunberg, SM; Ramlau, R; Roila, F; Rolski, J; Russo, MW	1
Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S	1
Albert, I; Arpornwirat, W; Bandekar, RR; Grunberg, SM; Hansen, VL; Levin, J	1
Blackburn, LM; Gridelli, C; Haiderali, AM; Lykopoulos, K; Russo, MW	1
Blackburn, L; Chung, F; Johnson, B; Kutsogiannis, DJ; Lane, SR; Levin, J; Pergolizzi, JV; Singla, NK; Singla, SK	1
Adams, LM; Bauman, J; Dandamudi, UB; Gartner, E; Hohl, R; Johnson, B; Lewis, LD; Morris, S; Murray, S; Webb, RT	1
Abissi, CJ; Hunt, CM; Papay, JI; Rich, DS; Russo, MW	1
Anixter, MB	1
Altorjay, A; Aqua, K; Blackburn, LM; Chinachoit, T; Kett, A; Lane, S; Levin, J; Melson, T; Pergolizzi, JV	1
Dube, P; Hesketh, PJ; Kopp, M; Lane, S; Levin, J; Makhson, A; Moiseyenko, V; Rosati, G; Russo, M; Wright, O	1

Trials

10 trial(s) available for ondansetron and casopitant

Article	Year
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:9 Topics: Adolescent; Adult; Antiemetics; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperazines; Piperidines; Vomiting; Young Adult	2009
Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperazines; Piperidines; Receptors, Neurokinin-1; Vomiting	2009
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Constipation; Cyclophosphamide; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Neutropenia; Ondansetron; Piperazines; Piperidines; Treatment Outcome; Vomiting	2009
Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemothera Cancer, 2009, Dec-15, Volume: 115, Issue:24 Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperazines; Piperidines; Vomiting	2009
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010, Volume: 18, Issue:11 Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Piperazines; Piperidines; Quality of Life; Surveys and Questionnaires; Vomiting; Young Adult	2010
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology, 2010, Volume: 113, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Antiemetics; Cholecystectomy, Laparoscopic; Constipation; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Gynecologic Surgical Procedures; Headache; Humans; Middle Aged; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperazines; Piperidines; Postoperative Nausea and Vomiting; Risk Factors; Treatment Outcome; Young Adult	2010
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Docetaxel; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Least-Squares Analysis; Leukocyte Count; Male; Middle Aged; Neoplasms; Neurokinin-1 Receptor Antagonists; Neutrophils; Ondansetron; Piperazines; Piperidines; Taxoids	2011
The evaluation of drug rechallenge: the casopitant Phase III program. Regulatory toxicology and pharmacology : RTP, 2010, Volume: 58, Issue:3 Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Male; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperazines; Piperidines; Serotonin Antagonists; Vomiting	2010
Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Archives of surgery (Chicago, Ill. : 1960), 2011, Volume: 146, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Incidence; Injections, Intravenous; Middle Aged; Neurokinin-1 Receptor Antagonists; Ondansetron; Piperazines; Piperidines; Postoperative Care; Postoperative Nausea and Vomiting; Retrospective Studies; Risk Factors; Treatment Outcome; United States; Young Adult	2011
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:7 Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Piperazines; Piperidines; Time Factors; Treatment Outcome; Vomiting	2012

Other Studies

1 other study(ies) available for ondansetron and casopitant

Article	Year
Why no casopitant-only arm? Anesthesiology, 2011, Volume: 114, Issue:1 Topics: Antiemetics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Ondansetron; Piperazines; Piperidines; Postoperative Nausea and Vomiting; Treatment Outcome	2011